Growth hormone-releasing hormone: structure, gene expression and molecular heterogeneity

Effect of salts on the structure of a potent analog of growth hormone releasing hormone as determined by optical spectroscopy

Optical spectroscopic methods (circular dichroism, analytical ultracentrifugation, and static light scattering) were employed to study the solution behavior of an N-terminal-acylated 76-residue analog of growth hormone releasing hormone (GHRH). The GHRH analog had a 30% helical configuration in aqueous acidic solution, unlike other GHRH analogs that had a random coil configuration in aqueous solutions, and self-associated. High concentrations (7 M) of urea were required to obtain monomeric peptide, but such urea concentrations unfolded the peptide. Therefore, the folding and self-association were related events. The self-association and helix content were increased by the addition of various cations (e.g., Na+, Ca2+). In 7 M urea, when these cations were added, the peptide started to refold toward its aqueous conformation in a pH dependent manner; at low pH (2.5-3.5) the peptide folded to approximately 50% of the native configuration. At neutral pH (> 6) only small changes were seen when salts were added. When CaCl2 was added to a solution containing 7 M urea at pH 2.5, the self-association of the peptide increased with the concentration of CaCl2. Therefore, the salt dependent self-association observed in aqueous solvents was present in 7 M urea. Residues 45-76 in this GHRH analog, which are not present outside the hypothalamus, are probably needed to interact with a folding chaperone in vivo and provide stability for successful membrane transport and maintenance of biological activity.

Production and biological activity of hybrid growth hormone-releasing hormone propeptides

Growth hormone-releasing hormone (GHRH), a hypothalamic hormone that stimulates the synthesis and release of growth hormone (GH) from anterior pituitary cells, has been previously produced by synthetic peptide chemistry and recombinant DNA procedures. GHRH is capable of stimulating growth as well as eliciting other anabolic effects on animals and thus may have potential applications in agriculture and human medicine. However, economical production of GHRH by recombinant DNA process has been difficult since GHRH is degraded rapidly by endogenous E. coli proteases. We report here an efficient process to produce hybrid GHRH analogs of higher molecular weight. These hybrid GHRH propeptides (proGHRH) are comprised of an analog of GHRH (44 aa) and the human GHRH carboxy-terminal peptide (33 aa). In E. coli K-12 RV308, the expression levels of the proGHRH analogs were estimated to be 10% of the total cellular protein. An in vitro assay to measure the release of rat growth hormone by GHRH analogs using crude E. coli lysates was also developed. This assay showed that the proGHRH analogs produced in E. coli efficiently stimulated GH release from rat anterior pituitary cells. One proGHRH analog, [alao]-proGHRH, was purified ans shown to efficiently elevate plasma GH levels in wether lambs. Our data indicate that the hybrid proGHRH peptides, unlike other hormone propeptides such as proinsulin, are remarkably bioactive.